Total
0
Shares
Source: Michael Johnson / Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in Melbourne
  • This trial will build on the existing data that confirms Rhinoswab is a superior method for sampling upper respiratory diseases such as SARS-CoV-2 (COVID-19) and influenza A and B
  • The Rhinoswab is a novel sampling technology that improves the sample collection process
  • It can be self administered, which RNO says makes sampling easier, more acceptable and more comfortable than traditional methods
  • Rhinomed ended the day 1.61 per cent in the red with shares trading at 30.5 cents

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in Melbourne.

This trial will build on the existing data that confirms Rhinoswab is a superior method for sampling upper respiratory diseases such as SARS-CoV-2 (COVID-19) and influenza A and B.

It will determine if users consider Rhinoswab more comfortable and convenient for sample collection and compare the sensitivity, specify and other measurement of the Rhinoswab compared to the traditional swab and saliva methods.

The trial will recruit 250 people and will be conducted over 30 to 50 days.

The Rhinoswab is a novel sampling technology that improves the sample collection process.

It can be self administered, which RNO said makes sampling easier, more acceptable and more comfortable than traditional methods.

CEO Michael Johnson commented on the trial.

“SARS-CoV-2 testing will be a part of our lives for some time to come. The Rhinoswab provides an easier, more standardised and comfortable sample collection method to encourage people to get tested, more often,” Mr Johnson said.

“There is clear evidence that vaccination and mass high frequency testing are the key tools we can use to keep our community safe – not just from SARS-CoV-2 but from all upper respiratory diseases including RSV and Influenza.”

“The Rhinoswab is a more effective and preferred method for testing people.”

Rhinomed has ended the day 1.61 per cent in the red with shares trading at 30.5 cents in a $77.41 million market cap.

RNO by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug